Moneycontrol PRO
LIVE NOW:Watch India’s Best Managed Companies 2021, Deloitte’s global marquee programme for private companies
you are here: HomeNewsBusiness

India in talks with Pfizer, COVID vaccine manufacturers for supply: Health Ministry

Pfizer said it was exploring opportunities to make this vaccine available for use in India

November 11, 2020 / 12:57 PM IST

The Health Ministry said on November 10 that its National Expert Group on Vaccine Administration for COVID-19 was in talks with “all candidate vaccine manufacturers” for supply to India.

Addressing his daily press conference, Union Health Secretary Rajesh Bhushan confirmed that India was considering a tie-up with Pfizer.

"The Group is in talks with all vaccine manufacturers, including domestic and foreign ones. When we continue this dialogue, we not only look at the status of the development of their vaccines, we also look at the regulatory approvals as to where they have progressed and we also engage in a dialogue about the logistical requirements,” Bhushan said.

Bhushan was questioned on the same after Pfizer and BioNTech on November 9 announced their candidate vaccine showed 90 percent effectiveness against COVID-19. The pharma giant has supply deals in place with the United States, the United Kingdom, Japan and the European Union.

"This is a continuously changing, dynamic situation and if and when the regulatory approval comes, we will share it with you," he added.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Also Read | Five things to know about Pfizer's COVID-19 vaccine that's 90% effective, including India availability

Pfizer meanwhile said it was aiming to produce up to 50 million vaccine doses in 2020 and 1.3 billion in 2021.

“If our vaccine candidate is successful, we would allocate the available 2020 doses proportionally across the countries where we have fully executed supply agreements that include delivery of a portion of doses in 2020,” the company told NDTV.

Pfizer added that it was “committed to ensure the availability” and will work with governments to “support distribution to their defined priority groups.”

Specifically on India, the company said it was “committed to engaging with the government” and will “explore opportunities to make this vaccine available for use in the country."

Follow our LIVE Updates on the coronavirus pandemic here

Apart from being able to secure enough vaccine stock from manufacturers, India’s poor cold chain infrastructure has been called to focus as most vaccines demand strict storage conditions.

Most of the COVID-19 vaccines in development require to be stored at such temperatures ranging 2-8 degree C to -50 and -90 degree C. There are concerns that storage and transportation issues could disallow proper country-wide vaccination programmes, even if India is able to secure sufficient doses.

Answering this Bhushan stated that “dialogue on logistical requirements is ongoing.”

“We are in a position to not only augment and strengthen, but also add to our cold chain capabilities. Any large scale immunisation (programme) would require substantial increase in the number of cold chain points and cold chain equipment,” he added.

Bhushan also reiterated that the vaccination drive, once in place, would be implemented for all. “Whenever regulatory approvals are provided, we have a plan to ensure that vaccines would be available to all priority population groups, irrespective of the region where they reside,” he noted.

Follow our full COVID-19 coverage here
Moneycontrol News
first published: Nov 11, 2020 12:57 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark